A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis

Trial Profile

A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Spondylarthritis
  • Focus Therapeutic Use
  • Acronyms Ability-3
  • Sponsors AbbVie
  • Most Recent Events

    • 08 Nov 2017 Results assessing the parameters of Objective Inflammation in Patients with Non-Radiographic Axial Spondyloarthritis, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism
    • 17 Jun 2017 Results from 28-Week open-label lead-in period presented at the 18th Annual Congress of the European League Against Rheumatism
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top